AZELAIC ACID
Relevant Data
Flavouring Substances Approved by European Union:
General Information
Mainterm | AZELAIC ACID |
CAS Reg.No.(or other ID) | 123-99-9 |
Regnum |
175.105 175.300 175.320 177.1200 177.1500 177.1630 177.1390 |
From www.fda.gov
Computed Descriptors
Download SDF2D Structure | |
CID | 2266 |
IUPAC Name | nonanedioic acid |
InChI | InChI=1S/C9H16O4/c10-8(11)6-4-2-1-3-5-7-9(12)13/h1-7H2,(H,10,11)(H,12,13) |
InChI Key | BDJRBEYXGGNYIS-UHFFFAOYSA-N |
Canonical SMILES | C(CCCC(=O)O)CCCC(=O)O |
Molecular Formula | C9H16O4 |
Wikipedia | azelaic acid |
From Pubchem
Computed Properties
Property Name | Property Value |
---|---|
Molecular Weight | 188.223 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 8 |
Complexity | 147.0 |
CACTVS Substructure Key Fingerprint | A A A D c e B w O A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A G g A A C A A A C A C A g A A A C A A A A g A I A A C Q C A A A A A A A A A A A A A E A A A A A A B I A A A A A Q A A E A A A A A A G I y K C A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A = = |
Topological Polar Surface Area | 74.6 |
Monoisotopic Mass | 188.105 |
Exact Mass | 188.105 |
Compound Is Canonicalized | True |
Formal Charge | 0 |
Heavy Atom Count | 13 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Isotope Atom Count | 0 |
Covalently-Bonded Unit Count | 1 |
From Pubchem
Food Additives Biosynthesis/Degradation
ADMET Predicted Profile --- Classification
Model | Result | Probability |
---|---|---|
Absorption | ||
Blood-Brain Barrier | BBB+ | 0.7397 |
Human Intestinal Absorption | HIA+ | 0.5731 |
Caco-2 Permeability | Caco2- | 0.6412 |
P-glycoprotein Substrate | Non-substrate | 0.6969 |
P-glycoprotein Inhibitor | Non-inhibitor | 0.9845 |
Non-inhibitor | 0.9229 | |
Renal Organic Cation Transporter | Non-inhibitor | 0.9359 |
Distribution | ||
Subcellular localization | Mitochondria | 0.8984 |
Metabolism | ||
CYP450 2C9 Substrate | Non-substrate | 0.8447 |
CYP450 2D6 Substrate | Non-substrate | 0.9050 |
CYP450 3A4 Substrate | Non-substrate | 0.7534 |
CYP450 1A2 Inhibitor | Non-inhibitor | 0.9046 |
CYP450 2C9 Inhibitor | Non-inhibitor | 0.9390 |
CYP450 2D6 Inhibitor | Non-inhibitor | 0.9729 |
CYP450 2C19 Inhibitor | Non-inhibitor | 0.9762 |
CYP450 3A4 Inhibitor | Non-inhibitor | 0.9600 |
CYP Inhibitory Promiscuity | Low CYP Inhibitory Promiscuity | 0.9927 |
Excretion | ||
Toxicity | ||
Human Ether-a-go-go-Related Gene Inhibition | Weak inhibitor | 0.9348 |
Non-inhibitor | 0.9602 | |
AMES Toxicity | Non AMES toxic | 0.9132 |
Carcinogens | Non-carcinogens | 0.8382 |
Fish Toxicity | High FHMT | 0.8783 |
Tetrahymena Pyriformis Toxicity | High TPT | 0.6559 |
Honey Bee Toxicity | High HBT | 0.6229 |
Biodegradation | Ready biodegradable | 0.8506 |
Acute Oral Toxicity | IV | 0.6448 |
Carcinogenicity (Three-class) | Non-required | 0.7514 |
From admetSAR
ADMET Predicted Profile --- Regression
Model | Value | Unit |
---|---|---|
Absorption | ||
Aqueous solubility | -1.8273 | LogS |
Caco-2 Permeability | 0.3625 | LogPapp, cm/s |
Distribution | ||
Metabolism | ||
Excretion | ||
Toxicity | ||
Rat Acute Toxicity | 1.3577 | LD50, mol/kg |
Fish Toxicity | 2.3886 | pLC50, mg/L |
Tetrahymena Pyriformis Toxicity | -0.3850 | pIGC50, ug/L |
From admetSAR
Toxicity Profile
Route of Exposure | Approximately 4% of the topically applied azelaic acid is systemically absorbed. |
---|---|
Mechanism of Toxicity | The exact mechanism of action of azelaic acid is not known. It is thought that azelaic acid manifests its antibacterial effects by inhibiting the synthesis of cellular protein in anaerobic and aerobic bacteria, especially <i>Staphylococcus epidermidis</i> and <i>Propionibacterium acnes</i>. In aerobic bacteria, azelaic acid reversibly inhibits several oxidoreductive enzymes including tyrosinase, mitochondrial enzymes of the respiratory chain, thioredoxin reductase, 5-alpha-reductase, and DNA polymerases. In anaerobic bacteria, azelaic acid impedes glycolysis. Along with these actions, azelaic acid also improves acne vulgaris by normalizing the keratin process and decreasing microcomedo formation. Azelaic acid may be effective against both inflamed and noninflamed lesions. Specifically, azelaic acid reduces the thickness of the stratum corneum, shrinks keratohyalin granules by reducing the amount and distribution of filaggrin (a component of keratohyalin) in epidermal layers, and lowers the number of keratohyalin granules. |
Metabolism | Mainly excreted unchanged in the urine but undergoes some b-oxidation to shorter chain dicarboxylic acids. Route of Elimination: Azelaic acid is mainly excreted unchanged in the urine, but undergoes some нф-oxidation to shorter chain dicarboxylic acids. Half Life: The observed half-lives in healthy subjects are approximately 45 minutes after oral dosing and 12 hours after topical dosing, indicating percutaneous absorption rate-limited kinetics. |
Toxicity Values | Oral LD50 in rat: >5 g/kg |
Lethal Dose | None |
Carcinogenicity (IARC Classification) | No indication of carcinogenicity to humans (not listed by IARC). |
Minimum Risk Level | None |
Health Effects | None |
Treatment | None |
Reference |
|
From T3DB
Taxonomic Classification
Kingdom | Organic compounds |
---|---|
Superclass | Lipids and lipid-like molecules |
Class | Fatty Acyls |
Subclass | Fatty acids and conjugates |
Intermediate Tree Nodes | Not available |
Direct Parent | Medium-chain fatty acids |
Alternative Parents | |
Molecular Framework | Aliphatic acyclic compounds |
Substituents | Medium-chain fatty acid - Dicarboxylic acid or derivatives - Carboxylic acid - Carboxylic acid derivative - Organic oxygen compound - Organic oxide - Hydrocarbon derivative - Organooxygen compound - Carbonyl group - Aliphatic acyclic compound |
Description | This compound belongs to the class of organic compounds known as medium-chain fatty acids. These are fatty acids with an aliphatic tail that contains between 4 and 12 carbon atoms. |
From ClassyFire
Targets
- General Function:
- Sterol 5-alpha reductase activity
- Specific Function:
- Converts testosterone (T) into 5-alpha-dihydrotestosterone (DHT) and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology.
- Gene Name:
- SRD5A2
- Uniprot ID:
- P31213
- Molecular Weight:
- 28393.015 Da
References
- Stamatiadis D, Bulteau-Portois MC, Mowszowicz I: Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol. 1988 Nov;119(5):627-32. [3207614 ]
- General Function:
- Steroid binding
- Specific Function:
- Efficiently catalyzes the reduction of progesterone, androstenedione, 17-alpha-hydroxyprogesterone and testosterone to 5-beta-reduced metabolites. The bile acid intermediates 7-alpha,12-alpha-dihydroxy-4-cholesten-3-one and 7-alpha-hydroxy-4-cholesten-3-one can also act as substrates.
- Gene Name:
- AKR1D1
- Uniprot ID:
- P51857
- Molecular Weight:
- 37376.615 Da
References
- Stamatiadis D, Bulteau-Portois MC, Mowszowicz I: Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol. 1988 Nov;119(5):627-32. [3207614 ]
- General Function:
- Protein homodimerization activity
- Specific Function:
- This is a copper-containing oxidase that functions in the formation of pigments such as melanins and other polyphenolic compounds. Catalyzes the rate-limiting conversions of tyrosine to DOPA, DOPA to DOPA-quinone and possibly 5,6-dihydroxyindole to indole-5,6 quinone.
- Gene Name:
- TYR
- Uniprot ID:
- P14679
- Molecular Weight:
- 60392.69 Da
References
- Nazzaro-Porro M, Passi S, Balus L, Breathnach A, Martin B, Morpurgo G: Effect of dicarboxylic acids on lentigo maligna. J Invest Dermatol. 1979 Jun;72(6):296-305. [448162 ]
- General Function:
- Zinc ion binding
- Specific Function:
- Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full length receptor. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform 1.
- Gene Name:
- ESR1
- Uniprot ID:
- P03372
- Molecular Weight:
- 66215.45 Da
References
- Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB: Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. [23611293 ]
- General Function:
- Thioredoxin-disulfide reductase activity
- Gene Name:
- trxB
- Uniprot ID:
- P66010
- Molecular Weight:
- 33615.84 Da
- General Function:
- Dna-directed dna polymerase activity
- Specific Function:
- In addition to polymerase activity, this DNA polymerase exhibits 3' to 5' and 5' to 3' exonuclease activity. It is able to utilize nicked circular duplex DNA as a template and can unwind the parental DNA strand from its template.
- Gene Name:
- polA
- Uniprot ID:
- P00582
- Molecular Weight:
- 103117.145 Da
From T3DB